ZENTIVA A SANOFI COMPANY Corporate Presentation

ZENTIVA: OUR MISSION

Zentiva mission is to increase the availability of modern high quality affordable generic medicines to more patients

W E A I M T O B E YO U R V A L U E D G E N E R I C S P A R T N E R

OUR MARKET POSITION ZENTIVA IS THE 3rd BIGGEST Gx PLAYER IN ITS TERRITORIES

1.204

2.507

2.433

MYLAN 1.147

BIOGARAN/EGIS 972

STADA 963

KRKA 527

GEDEON RICHTER 404

MENARINI 362

ACTAVIS 358

TEVA

SANDOZ

ZENTIVA

1

2

3

4

5

6

7

8

9

10

in Bn EURO, 2011

OUR MARKETS WE HAVE A WIDE GEOGRAPHICAL COVERAGE ACROSS EUROPE WITH GLOBAL PERSPECTIVES

Zentiva • Operates in more than 35 markets

across Europe and beyond.

• Employs around 3,000 employees in its commercial operations.

• Industrial affairs add another 3,000 employees to the Zentiva community.

• Reaches out to a target population of over 800 million patients.

• Prague headquarters is the decision making centre for strategy and global R&D for Sanofi Gx business worldwide.

OUR ORIGINS Z E N T I V A H A S A L O N G H I S T O R Y O F P R O D U C I N G

H I G H Q U A L I T Y P H A R M A C E U T I C A L S

1488 1930 1998 2000 2003 2004 2005 2007 2009 2011 2012

Zentiva traces its origins back to the “At the Black Eagle” Pharmacy in Prague

Zentiva listed on the Prague and London Stock Exchanges

Zentiva acquired Eczacibaci Generic Pharmaceuticals, a leading pharmaceutical company in Turkey

Management buyout

Acquisition of Slovakofarma + Launch of the Zentiva corporate brand

Zentiva acquired Sicomed, the leading generics company in Romania

Zentiva recognized

as Generics Business of Sanofi Group

Manufacturing beings at Prague site

Business

Rationalisation

Positioned for Regional Growth

Leading CEE Player Expanding Internationally

Zentiva combined with Sanofi

Zentiva entered Western Europe through rebranding of Winthrop and Helvepharm

Zentiva leads global Sanofi‘s Gx portfolio strategy and development

OUR THERAPEUTIC AREAS

C A R D I O V A S C U L A R

F E M A L E H E A L T H C A R E

R E S P I R A T O R Y

A N T I - I N F E C T I V E S & A N T I - F U N G A L S

U R O L O G Y

C N S

P A I N

G A S T R O I N T E S T I N A L

OUR INDUSTRIAL AFFAIRS WE ARE ONE OF LARGEST PRODUCERS OF AFFORDABLE MEDICINES BASED IN EUROPE EMPLOYING AROUND 3,000 PEOPLE WITH A TOTAL PRODUCTION OF ALMOST 450M PACKS

TR / Lüleburgaz DP Development and Production

DE / Munich Respiratory Development

CZ / Prague API and DP Development, Pharma Production

SK / Hlohovec API and Pharma Production, DP Development

RO / Bucharest Pharma Production

DP: drug product | API: Active pharmaceutical ingredient

Munich

Prague

Hlohovec

Bucharest

Lüleburgaz

HC: 808 people

HC: 882 people

HC: 399 people

HC: 816 people

HC: 72 people

OUR RESPONSIBILITY ZENTIVA SUSTAINABILITY APPROACH PLACES THE PATIENT AT THE HEART OF ITS BUSINESS CONDUCT. THIS APPROACH IS BASED ON FOUR KEY AREAS:

PAT I E N T

P E O P L E

E T H I C S

P L A N E T

Zent iva Group a .s .

U Kabe lovny 130 / / 102 37 Prague 10 / / Czech Repub l i c

Phone : (+420) 267 241 111 / / E -ma i l : zen t i va@zent i va .com

www.zent iva .com

WE ARE

ZENTIVA